相似文献
1
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias.
Blood. 2017 Jul 6;130(1):91-94. doi: 10.1182/blood-2017-01-764951. Epub 2017 Apr 26.
2
Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!
Oncologist. 2017 Sep;22(9):1125-1134. doi: 10.1634/theoncologist.2017-0009. Epub 2017 May 25.
3
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.
J Clin Oncol. 2019 Feb 10;37(5):375-385. doi: 10.1200/JCO.2018.79.2184. Epub 2018 Nov 7.
4
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2006 May;12(5):511-7. doi: 10.1016/j.bbmt.2006.01.006.
5
Young and Restless: Expansion of Donor-Origin Mutant HSCs after Transplantation.
Cell Stem Cell. 2020 Mar 5;26(3):305-306. doi: 10.1016/j.stem.2020.01.022.
6
Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients.
Bone Marrow Transplant. 2017 Apr;52(4):634-637. doi: 10.1038/bmt.2016.332. Epub 2016 Dec 19.
7
Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
Bone Marrow Transplant. 1996 Dec;18(6):1081-6.
8
Second allografts for relapsed hematologic malignancies: feasibility of using a different donor.
Bone Marrow Transplant. 2005 Feb;35(3):261-4. doi: 10.1038/sj.bmt.1704761.
9
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.
10
Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.
引用本文的文献
1
Allogeneic Transplantation for Older Adults.
Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.
2
Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.
Cancers (Basel). 2024 Dec 9;16(23):4118. doi: 10.3390/cancers16234118.
3
Characterization of clonal dynamics using duplex sequencing in donor-recipient pairs decades after hematopoietic cell transplantation.
Sci Transl Med. 2024 Oct 23;16(770):eado5108. doi: 10.1126/scitranslmed.ado5108.
4
Influence of the Bone Marrow Microenvironment on Hematopoietic Stem Cell Behavior Post-Allogeneic Transplantation: Development of Clonal Hematopoiesis and Telomere Dynamics.
Int J Mol Sci. 2024 Sep 24;25(19):10258. doi: 10.3390/ijms251910258.
5
Hematopoietic stem cell transplantation: an Italian monocentric experience on the health assessment and eligibility of adult-related donors.
Front Oncol. 2024 May 30;14:1389068. doi: 10.3389/fonc.2024.1389068. eCollection 2024.
6
Clonal hematopoiesis in the setting of hematopoietic cell transplantation.
Semin Hematol. 2024 Feb;61(1):9-15. doi: 10.1053/j.seminhematol.2024.01.011. Epub 2024 Feb 1.
7
Causes and consequences of clonal hematopoiesis.
Blood. 2023 Dec 28;142(26):2235-2246. doi: 10.1182/blood.2023022222.
8
Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation.
J Hematol. 2023 Jun;12(3):138-144. doi: 10.14740/jh1124. Epub 2023 Jun 30.
9
Clonal haematopoiesis and dysregulation of the immune system.
Nat Rev Immunol. 2023 Sep;23(9):595-610. doi: 10.1038/s41577-023-00843-3. Epub 2023 Mar 20.
10
Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing.
Biomedicines. 2023 Jan 26;11(2):359. doi: 10.3390/biomedicines11020359.
本文引用的文献
1
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
Science. 2017 Feb 24;355(6327):842-847. doi: 10.1126/science.aag1381. Epub 2017 Jan 19.
2
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.
3
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.
4
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Lancet Oncol. 2017 Jan;18(1):100-111. doi: 10.1016/S1470-2045(16)30626-X. Epub 2016 Dec 3.
5
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.
Nat Commun. 2016 Aug 22;7:12484. doi: 10.1038/ncomms12484.
6
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.
Biol Blood Marrow Transplant. 2016 Nov;22(11):2100-2103. doi: 10.1016/j.bbmt.2016.08.002. Epub 2016 Aug 4.
7
Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.
J Mol Diagn. 2016 Jul;18(4):507-15. doi: 10.1016/j.jmoldx.2016.02.003.
8
Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.
Leukemia. 2016 Sep;30(9):1916-1920. doi: 10.1038/leu.2016.63. Epub 2016 Mar 15.
9
Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation.
Leukemia. 2016 Aug;30(8):1742-5. doi: 10.1038/leu.2016.23. Epub 2016 Feb 12.
10
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
Blood. 2016 Jan 14;127(2):260-7. doi: 10.1182/blood-2015-08-663823. Epub 2015 Nov 2.
Zotero 插件